Enlivex Therapeutics LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital and Steven Boyd have filed an amendment to their Schedule 13G, disclosing a 4.99% beneficial ownership in Enlivex Therapeutics Ltd.'s Ordinary Shares.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 7.53% of Enlivex Therapeutics Ltd.'s ordinary shares as of March 31, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a beneficial ownership of 9.75% of Enlivex Therapeutics Ltd.'s Ordinary Shares as of December 31, 2024.